FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007146260> ?p ?o ?g. }

• W2007146260 endingPage "3809" @default.
• W2007146260 startingPage "3809" @default.
• W2007146260 abstract "Purpose.: Uveitis is a common cause of vision loss. The renin angiotensin system (RAS), which plays a vital role in cardiovascular system, is a potent mediator of inflammation and has been implicated in the pathogenesis of uveitis. A newly identified axis of RAS, ACE2/Ang-(1-7)/Mas, has emerged as a novel target because it counteracts the deleterious effect of angiotensin II. The purpose of this study was to investigate the effect of endogenous ACE2 activation in preventing endotoxin-induced uveitis (EIU) in mice. Methods.: ACE2 activator diminazene aceturate (DIZE) was administered both systemically and locally. For systemic administration, female BALB/c mice received intraperitoneal injection of DIZE (60 mg/kg body weight [BW]) for 2 days prior to lipopolysaccharide (LPS) intravitreal injection (125 ng) to induce uveitis. For local study, DIZE was given at 0.5, 0.1, and 0 mg/mL as eyedrops six times per day for 2 days before LPS injection. The anterior segment of the mice was examined at 12, 24, 48, and 72 hours after LPS injection, and clinical scores were determined at the same time. Morphology and infiltrating inflammatory cells were evaluated after 24 hours. The mRNA levels of inflammatory cytokines were analyzed by real-time RT-PCR. ACE2 activity was determined using a self-quenching fluorescent substrate. Results.: At 24 hours, the clinical score of mice treated with DIZE systemically was significantly lower (mean, ∼1.75) than the saline vehicle group (mean, ∼4) (P < 0.001). Histological examination showed 63.4% reduction of infiltrating inflammatory cells in the anterior segment and 57.4% reduction in the posterior segment of DIZE-treated eyes. The number of CD45+ inflammatory cells in the vitreous of the DIZE-treated group was decreased (43.3%) compared to the vehicle group (P < 0.01). The mRNA levels of inflammatory cytokines were significantly reduced in the DIZE-treated group (P < 0.01, P < 0.001). The number of infiltrating inflammatory cells was also significantly reduced in eyes that received topical administration of DIZE: 73.8% reduction in the 0.5 mg/mL group and 51.7% reduction in the 0.1mg/mL group compared to the control group. DIZE treatment resulted in significantly increased ACE2 activity in the retina (P < 0.001). Conclusions.: Endogenous ACE2 activation by DIZE has a preventive effect on LPS-induced ocular inflammation in the EIU mouse model. These results support the notions that RAS plays a role in modulating ocular immune response and that enhancing ACE2 provides a novel therapeutic strategy for uveitis." @default.
• W2007146260 created "2016-06-24" @default.
• W2007146260 creator A5004045598 @default.
• W2007146260 creator A5011128580 @default.
• W2007146260 creator A5014912512 @default.
• W2007146260 creator A5022928434 @default.
• W2007146260 creator A5049808310 @default.
• W2007146260 creator A5062323892 @default.
• W2007146260 creator A5064648564 @default.
• W2007146260 date "2014-06-17" @default.
• W2007146260 modified "2023-10-01" @default.
• W2007146260 title "Angiotensin-Converting Enzyme 2 (ACE2) Activator Diminazene Aceturate Ameliorates Endotoxin-Induced Uveitis in Mice" @default.
• W2007146260 cites W1232970536 @default.
• W2007146260 cites W124614369 @default.
• W2007146260 cites W1483848921 @default.
• W2007146260 cites W1485797085 @default.
• W2007146260 cites W1493720279 @default.
• W2007146260 cites W1506891139 @default.
• W2007146260 cites W1852634308 @default.
• W2007146260 cites W1974985368 @default.
• W2007146260 cites W1977227434 @default.
• W2007146260 cites W1987316389 @default.
• W2007146260 cites W1992024672 @default.
• W2007146260 cites W1992557795 @default.
• W2007146260 cites W1993643603 @default.
• W2007146260 cites W1997031423 @default.
• W2007146260 cites W2000040025 @default.
• W2007146260 cites W2008054951 @default.
• W2007146260 cites W2019449356 @default.
• W2007146260 cites W2021345753 @default.
• W2007146260 cites W2022478196 @default.
• W2007146260 cites W2028254334 @default.
• W2007146260 cites W2033332566 @default.
• W2007146260 cites W2036298420 @default.
• W2007146260 cites W2037183160 @default.
• W2007146260 cites W2039389449 @default.
• W2007146260 cites W2052645339 @default.
• W2007146260 cites W2055736315 @default.
• W2007146260 cites W2057764408 @default.
• W2007146260 cites W2060898700 @default.
• W2007146260 cites W2075032331 @default.
• W2007146260 cites W2075138825 @default.
• W2007146260 cites W2075604884 @default.
• W2007146260 cites W2082951653 @default.
• W2007146260 cites W2086176437 @default.
• W2007146260 cites W2087563625 @default.
• W2007146260 cites W2106607972 @default.
• W2007146260 cites W2118638261 @default.
• W2007146260 cites W2121000910 @default.
• W2007146260 cites W2124460853 @default.
• W2007146260 cites W2134899427 @default.
• W2007146260 cites W2138043907 @default.
• W2007146260 cites W2138658531 @default.
• W2007146260 cites W2139065428 @default.
• W2007146260 cites W2140325630 @default.
• W2007146260 cites W2142286274 @default.
• W2007146260 cites W2148802014 @default.
• W2007146260 cites W2164226477 @default.
• W2007146260 cites W2327161687 @default.
• W2007146260 cites W2419060044 @default.
• W2007146260 cites W263358538 @default.
• W2007146260 cites W5411299 @default.
• W2007146260 cites W62851129 @default.
• W2007146260 cites W103429211 @default.
• W2007146260 cites W120816120 @default.
• W2007146260 cites W2107371634 @default.
• W2007146260 cites W91340801 @default.
• W2007146260 doi "https://doi.org/10.1167/iovs.14-13883" @default.
• W2007146260 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4062403" @default.
• W2007146260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24854854" @default.
• W2007146260 hasPublicationYear "2014" @default.
• W2007146260 type Work @default.
• W2007146260 sameAs 2007146260 @default.
• W2007146260 citedByCount "69" @default.
• W2007146260 countsByYear W20071462602014 @default.
• W2007146260 countsByYear W20071462602015 @default.
• W2007146260 countsByYear W20071462602016 @default.
• W2007146260 countsByYear W20071462602017 @default.
• W2007146260 countsByYear W20071462602018 @default.
• W2007146260 countsByYear W20071462602019 @default.
• W2007146260 countsByYear W20071462602020 @default.
• W2007146260 countsByYear W20071462602021 @default.
• W2007146260 countsByYear W20071462602022 @default.
• W2007146260 countsByYear W20071462602023 @default.
• W2007146260 crossrefType "journal-article" @default.
• W2007146260 hasAuthorship W2007146260A5004045598 @default.
• W2007146260 hasAuthorship W2007146260A5011128580 @default.
• W2007146260 hasAuthorship W2007146260A5014912512 @default.
• W2007146260 hasAuthorship W2007146260A5022928434 @default.
• W2007146260 hasAuthorship W2007146260A5049808310 @default.
• W2007146260 hasAuthorship W2007146260A5062323892 @default.
• W2007146260 hasAuthorship W2007146260A5064648564 @default.
• W2007146260 hasBestOaLocation W20071462602 @default.
• W2007146260 hasConcept C126322002 @default.
• W2007146260 hasConcept C134018914 @default.
• W2007146260 hasConcept C16613235 @default.
• W2007146260 hasConcept C170493617 @default.
• W2007146260 hasConcept C185592680 @default.

• next